Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Levofloxacin (Fluoroquinolone) is a broad-spectrum antibiotic topoisomerase II and topoisomerase IV inhibitor, used to treat respiratory, urinary tract, gastrointestinal, and abdominal infections.
パッケージサイズ | 在庫状況 | 単価(税別) | |||
---|---|---|---|---|---|
サンプルについてお問い合わせ | |||||
100 mg | 在庫あり | ¥ 11,000 | |||
5 g | 在庫あり | ¥ 17,500 | |||
1 mL * 10 mM (in DMSO) | 在庫あり | ¥ 11,500 |
説明 | Levofloxacin (Fluoroquinolone) is a broad-spectrum antibiotic topoisomerase II and topoisomerase IV inhibitor, used to treat respiratory, urinary tract, gastrointestinal, and abdominal infections. |
In vitro | Levofloxacin is active against most aerobic Gram-positive and Gram-negative organisms and demonstrates moderate?activity?against anaerobes.[1] Levofloxacin is two-fold more active than ciprofloxacin against Streptococcus pneumoniae and 2- to 4-fold more active than ciprofloxacin against Staphylococcus aureus, Xanthomonas maltophilia, and Bacteroides fragilis. Levofloxacin is two- to eightfold more?active?than ciprofloxacin against coagulase-negative staphylococci and Acinetobacter spp., although these improvements in potency may not be clinically relevant.?Levofloxacin?inhibits 90% of streptococci when it is used at concentrations of 1 mg/mL to 2 mg/mL. [2] Levofloxacin?exhibits twofold greater?inhibitory?and?bactericidal?activities?than ofloxacin?against?either extracellular or intracellular tubercle bacilli.?[3] Levofloxacin?has the least?inhibitory?effect on osteoblastic cell growth, with a 50%?inhibitory concentration of approximately 80 mg/mL at 48 and 72 hours. Levofloxacin results in strong inhibition of calcium deposition, as determined on day 14 by alizarin red staining and biochemical analysis.[4] Levofloxacin inhibits glycosaminoglycan synthesis initially and DNA synthesis and mitochondrial function secondarily at actual arthropathic concentrations in cultured rabbit chondrocytes but that these changes are reversible and not enough to kill the cells. [5] |
In vivo | Levofloxacin is as efficacious as or more efficacious than that with ciprofloxacin in systemic as well as pyelonephritis infections in mice. Levofloxacin achieves higher concentrations in the serum and tissue of mice than does ciprofloxacin. [2] |
別名 | Levaquin, Cravit, Tavanic, Fluoroquinolone, (-)-Ofloxacin |
分子量 | 361.37 |
分子式 | C18H20FN3O4 |
CAS No. | 100986-85-4 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 12.5 mg/mL (34.59 mM)
Ethanol: 2 mg/mL(5.5 mM)
H2O: 9 mg/mL (24.9 mM)
You can also refer to dose conversion for different animals. 詳細
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Levofloxacin 100986-85-4 DNA Damage/DNA Repair Microbiology/Virology Topoisomerase Antibacterial Antibiotic Orthopoxvirus BK Viremia Levaquin inhibit Inhibitor Cravit DNA gyrase Tavanic airway inflammation Fluoroquinolone DNA/RNA Synthesis Bacterial Ofloxacin (-)-Ofloxacin chronic periodontitis inhibitor